This article is informational only. It summarizes publicly documented pharmacopeial monograph specifications for talc as it applies to physical excipient performance. It does not certify, test, or make any claim about the compliance status of any specific PlaxRaw shipment, and it is not a substitute for a buyer’s own testing and qualification program. Always verify current requirements directly against the applicable monograph and your own compliance documentation.
A talc lot can pass an identity test and still cause inconsistent tablet weight on the press, because glidant performance is driven by particle size distribution — a separate, specifically tested parameter — not by the material’s chemical identity alone.
Root Causes
Talc functions in solid-dosage formulations as a glidant and lubricant: it works by adsorbing onto the surface of larger drug and diluent particles and reducing particle-particle adhesive and cohesive forces, which is a mechanical, particle-surface effect rather than a chemical one. Because the mechanism is physical, it is directly sensitive to particle size — a talc lot with a coarser or more variable particle size distribution than the material a formulation was originally qualified against will coat powder surfaces differently and change how the blend flows into the die.
The USP-NF Talc monograph reflects this by setting explicit physical-purity specifications alongside chemical ones: a minimum purity threshold, a maximum limit on acid-insoluble substances (around 0.5%), and a ceiling on the proportion of oversize particles — commonly cited as no more than 3% retained on a 75-micron sieve. These are pass/fail limits on the distribution’s coarse tail, not a target for the whole distribution, which means two lots can both be “in spec” against the monograph’s ceiling while still differing meaningfully in their median particle size and overall distribution shape — and that difference is exactly what shows up as inconsistent flow and content uniformity on the press.
USP General Chapter <1059> Excipient Performance addresses this gap directly: it treats particle size distribution as a functionality-related characteristic (FRC) of an excipient — a property that affects how the excipient performs in a specific process, distinct from and in addition to the compendial identity/purity requirements. For a glidant, particle size distribution is one of the primary FRCs, because flow behavior is fundamentally a function of how the particles are sized and shaped, not just what they are chemically. The USP Talc monograph itself is also under active revision — its implementation timeline was extended into 2026 specifically around improved analytical detection methods — a reminder that monograph specifications for this material are not static.
What This Means for Raw Material Selection
Request the full particle size distribution report (not just a pass/fail statement against the monograph’s oversize-particle ceiling) for any talc lot intended for glidant use, and compare it against the distribution profile of the lot your formulation was originally qualified with — a lot that passes the monograph limit can still differ enough in median size to change flow behavior. Treat particle size distribution as a functionality-related characteristic under the USP <1059> framework, meaning it should be specified and monitored as a process-critical parameter in its own right, not folded into a general “meets USP talc monograph” statement. Confirm which monograph revision a supplier’s data is tested against, since the talc monograph’s analytical methods are actively being updated, and ask what test method (sieve analysis, laser diffraction, or another technique) generated the particle size data, since different methods can report different distribution profiles for the same physical lot.
Sources: USP-NF General Chapter <1059> Excipient Performance; USP-NF Talc monograph; USP “FAQs: Modernization of the USP Talc Monograph” (usp.org); Pharma Excipients technical overview, “Introduction to Talc as a Pharmaceutical Excipient” (pharmaexcipients.com). This article does not verify or certify compliance with any specific pharmacopeial monograph for any PlaxRaw product.
